Background
Methods
Study design and population
Quantitative coronary angiography
Study endpoints and definitions
Statistical analysis
Results
Baseline lesion analysis and ischemia driven revascularization
Clinical Factors | IDR (+) (20 patients) | IDR (−) (300 patients) | P value |
---|---|---|---|
Age (years old) | 62.5 ± 9.9 | 65.9 ± 10.3 | 0.152 |
BMI (kg/m2) | 24.3 ± 3.2 | 24.8 ± 2.9 | 0.449 |
Gender (male), n (%) | 16 (80.0) | 223 (74.1) | 0.557 |
Previous PCI, n (%) | 2 (10.0) | 35 (11.6) | 0.825 |
Previous CABG, n (%) | 1 (5.0) | 3 (1.0) | 0.119 |
Previous MI, n (%) | 2 (10.0) | 22 (7.3) | 0.661 |
Previous CHF, n (%) | 3 (1.0) | 0 (0.0) | 0.816 |
Diabetes mellitus, n (%) | 12 (60.0) | 96 (31.9) | 0.010 |
Hypertension, n (%) | 13 (65.0) | 213 (70.8) | 0.584 |
CRF, n (%) | 2 (10.0) | 7 (2.3) | 0.044 |
Dyslipidemia, n (%) | 9 (45.0) | 190 (63.1) | 0.106 |
Current smoking, n (%) | 13 (65.0) | 164 (55.2) | 0.394 |
FHx of CAD, n (%) | 1 (5.0) | 35 (11.7) | 0.610 |
Clinical diagnosisa, n (%) | 60.0 / 25.0 / 5.0 / 10.0 | 64.7 / 18.7 / 10.7 / 6.0 | 0.616 |
Diagnosis of ACS, n (%) | 8 (40.0) | 106 (35.5) | 0.688 |
LV ejection fraction (%) | 61.2 ± 7.9 | 59.7 ± 8.8 | 0.482 |
WBC (109/L) | 7200 ± 2200 | 6800 ± 2300 | 0.550 |
Hemoglobin (g/dL) | 13.8 ± 1.8 | 13.5 ± 1.8 | 0.485 |
Creatinine(mg/dL) | 1.49 ± 1.43 | 1.08 ± 0.65 | 0.215 |
- eGFR (ml/min/1.73m2) | 63.6 ± 28.4 | 72.9 ± 20.4 | 0.056 |
HbA1c (%) | 7.2 ± 1.8 | 7.0 ± 1.0 | 0.693 |
Total cholesterol (mg/dl) | 161 ± 31 | 157 ± 40 | 0.667 |
Triglyceride (mg/dl) | 135 ± 56 | 136 ± 85 | 0.935 |
HDL-cholesterol (mg/dl) | 44 ± 9 | 43 ± 11 | 0.585 |
LDL-cholesterol (mg/dl) | 98 ± 31 | 97 ± 36 | 0.870 |
CRP (mg/dl) | 0.41 ± 1.13 | 0.42 ± 1.23 | 0.981 |
Discharge Medications | |||
- Aspirin | 20 (100%) | 299 (99.7%) | 0.796 |
- Clopidogrel | 20 (100%) | 299 (99.7%) | 0.796 |
- Beta blocker | 17 (85.0%) | 213 (71.0%) | 0.178 |
- ARB / ACE inhibitors | 13 (65.0%) | 140 (46.7%) | 0.112 |
- Calcium channel blockers | 5 (25.0%) | 63 (21.0%) | 0.672 |
- Statins | 20 (100%) | 296 (98.7%) | 0.603 |
- High intensity statin | 3 (15.0%) | 77 (25.9%) | 0.778 |
Lesion factors | IDR (+) (20 lesions) | IDR (−) (620 lesions) | P |
Lesion length (mm) | 16.14 ± 14.79 | 11.25 ± 7.35 | 0.157 |
Lesion locationb, (%) | 30.0/40.0/30.0/0.0 | 34.5/27.9/37.3/0.2 | 0.692 |
Lesion proximityc, (%) | 20.0 / 15.0 / 30.0 / 30.0 | 26.5 / 24.8 / 27.5 / 24.5 | 0.703 |
Lesion typed, (%) | 30.0 / 10.0 / 30.0 / 30.0 | 34.8 / 31.3 / 21.9 / 11.9 | 0.035 |
B2/C lesion type | 12 (60.0%) | 210 (33.9%) | 0.016 |
Minimal lumen diameter (mm) | 1.31 ± 0.49 | 1.59 ± 0.49 | 0.013 |
Reference diameter (mm) | 2.86 ± 0.52 | 2.84 ± 0.57 | 0.868 |
Initial DS | 54.3 ± 13.1% | 44.8 ± 10.3% | < 0.001 |
Last DS | 75.8 ± 14.8 | 47.9 ± 10.7% | < 0.001 |
Delta DS | 22.1 ± 15.4% | 3.1 ± 5.8% | < 0.001 |
QCA analysis of the natural progression of atherosclerotic plaques
Predictors of progression
Group 1a | Group 2a | Group 3a | P value | ||
---|---|---|---|---|---|
No risk factors | 1 risk factor | 2 risk factors | |||
Initial DS | 42.9 ± 9.6% | 46.0 ± 11.0% | 48.8 ± 10.5% | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.001 | ||||
Group 2 vs. Group 3 | 0.075 | ||||
Group 1 vs. Group 3 | < 0.001 | ||||
Final DS | 46.0 ± 9.7% | 49.5 ± 12.0% | 55.5 ± 14.6% | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.001 | ||||
Group 2 vs. Group 3 | < 0.001 | ||||
Group 1 vs. Group 3 | < 0.001 | ||||
Delta DS | 3.0 ± 6.8% | 3.5 ± 6.1% | 6.8 ± 9.9% | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.703 | ||||
Group 2 vs. Group 3 | 0.001 | ||||
Group 1 vs. Group 3 | < 0.001 | ||||
Velocity of DS progression | 0.150 ± 0.402%/month | 0.154 ± 0.298%/month | 0.422 ± 0.956%/month | Overall | < 0.001 |
Group 1 vs. Group 2 | 0.995 | ||||
Group 2 vs. Group 3 | < 0.001 | ||||
Group 1 vs. Group 3 | < 0.001 |